Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage company developing oral Nav1.8 ion channel inhibitors for pain.
SCHEDULE 13GNov 16Latest SEC filing
Nov 5Latest story
Latigo Biotherapeutics is a clinical-stage company developing oral Nav1.8 ion channel inhibitors for pain.
November 2026
September 2026
August 2026
July 2026